ASH 2020 | alloHCT plus fludarabine and treosulfan for secondary AML
Eleni Gavriilaki
• 20 Nov 2020
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses a retrospective real-world study exploring whether allogeneic hematopoietic cell transplantation (alloHCT) with a myeloablative conditioning regimen of reduced toxicity, fludarabine and treosulfan (FluTreo), has a long-term survival advantage over previous transplant modalities for secondary acute myeloid leukemia (AML). The results showed the overall survival, relapse rates and graft-versus-host disease were all comparable with FluTreo to other transplants, allowing extension of the allo-HCT eligible population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
